“Help more people find care that fits their lives.”

— Joe Nadglowski, Obesity Action Coalition, on new obesity drugs, via Healio
Ranked bar chart of weight loss in headline trials, colored by status: retatrutide 28.3%, EloraTZP 23.3%, CagriSema 22.7% under review, Zepbound 20.9% approved, eloralintide 20.1%, MariTide about 20%, survodutide 16.6%, Wegovy 14.9% approved, Wegovy pill 13.6% approved, Foundayo 12.4% approved
The top of the board is orange: not available yet. The best you can get today is green.

In this post you’ll learn every major weight-loss drug in the 2026 pipeline, ranked by trial results and sorted by how soon you can actually get it. It’s our hub page; each drug links to a deeper breakdown. About 6 minutes.

The Leaderboard Problem

Every week, someone posts a “best weight-loss drug” ranking. Biggest number wins.

But the drug at the top usually isn’t approved. The trials ran for different lengths. Some had people with diabetes, who tend to lose less. And nobody mentions the quit rate.

A number with no timeline, no trial details and no pharmacy doesn’t tell you much. So this board ranks the numbers, then sorts them by what you can actually do today.

Action item: For any drug on any ranking, ask three things: Is it approved? How long was the trial? Did people have diabetes?

Tier 1: Weight-Loss Drugs Approved and Available Now

These are the four you can talk to your doctor about today.

  • Zepbound (tirzepatide), weekly shot: 20.9% at 72 weeks. The strongest approved option. Cash price $299 to $449 a month with Lilly’s offer.
  • Wegovy (semaglutide), weekly shot: 14.9% at 68 weeks.
  • Wegovy pill (oral semaglutide), daily: 13.6% at 64 weeks. Approved December 2025. Strict rules: empty stomach, a little water, then wait 30 minutes.
  • Foundayo (orforglipron), daily pill: 12.4% at 72 weeks for people who stayed on it. Approved April 2026, with no food or water rules. Cash price $149 to $299 a month.

Deep dives: Foundayo vs Zepbound and Foundayo Side Effects.

Action item: If you’re ready to start, this is your real menu. Ask your insurer which of these four is covered.

Tier 2: Under FDA Review

CagriSema (Novo Nordisk) pairs semaglutide with the amylin drug cagrilintide. It reached 22.7% at 68 weeks for people who stayed on it, and 15.7% in people with type 2 diabetes.

Novo filed it in December 2025, and a decision is expected in the fourth quarter of 2026. As of October 21, 2026, it’s not approved. One knock: in a head-to-head trial, it lost to Zepbound, 23.0% vs 25.5%.

Deep dive: CagriSema vs EloraTZP.

Action item: Watch for CagriSema’s FDA decision before the end of 2026. It’s the next drug likely to reach pharmacies.

Tier 3: The Weight-Loss Drug Pipeline in Phase 3

  • Retatrutide (Lilly), a triple-hormone weekly shot: 28.3% at 80 weeks, the highest of any drug here. Lilly plans to file in Q1 2027. See When Will Retatrutide Be Available?
  • EloraTZP (Lilly), amylin plus tirzepatide: 23.3% at 48 weeks in people with type 2 diabetes, in Phase 2. Phase 3 starts by the end of 2026. See Retatrutide vs EloraTZP.
  • Eloralintide (Lilly), amylin alone: 20.1% at 48 weeks in Phase 2. Now in Phase 3. See Amylin Drugs Explained.
  • MariTide (Amgen), a shot taken monthly or less often: about 20% at 52 weeks. In Phase 3.
  • Survodutide (Boehringer Ingelheim and Zealand): 16.6% at 76 weeks, with Phase 3 results reported in 2026.
  • Zenagamtide, formerly amycretin (Novo Nordisk), one molecule hitting amylin and GLP-1: in Phase 3.

New pills are coming too. Structure Therapeutics’ aleniglipron (15.3% at 44 weeks) and AstraZeneca’s elecoglipron (11.8% at 36 weeks) both moved into Phase 3 in 2026, per Ozmosi’s pipeline tracker.

Action item: If you’re waiting for one of these, put a realistic date on it. Most are 2028 or later.

The Fine Print That Reorders the Board

Diabetes changes everything. People with type 2 diabetes usually lose less weight on these drugs. EloraTZP’s 23.3% came from people with diabetes, which makes it more impressive than it looks.

Time matters. Retatrutide’s 28.3% took 80 weeks. Many others stopped at 48 to 72.

Quit rates matter. EloraTZP’s quit rate due to side effects ran 10.8% to 27% in Phase 2. Foundayo’s top dose was 10.3%. A drug only works if you can stay on it.

Action item: When you compare two drugs, find the quit rate for each. If you can’t find it, that’s a red flag.

A Worked Example: Three People, Three Picks

Here’s how the board might shape a conversation with a doctor. These are illustrations, not recommendations.

  • Maya hates needles and pays cash. Foundayo is the obvious question: a daily pill, no meal rules, from $149 a month.
  • Dev wants the most weight loss available today. Zepbound is the strongest approved drug at 20.9%. Retatrutide is stronger, but not until 2027 at the earliest.
  • Rosa has type 2 diabetes and is curious about what’s next. She starts with what’s approved now and keeps an eye on EloraTZP and CagriSema, whose diabetes data are most relevant to her.

Notice that none of them picked the top of the board. Availability, price, and personal health decided first.

Action item: Write your own one-line version: your blocker, your goal, your health context. Bring it to your appointment.

Whatever Weight-Loss Drug You Take, You Still Eat

None of these drugs replace meals. They change how meals feel. Four medical societies said it plainly in a 2025 advisory: the medicines alone aren’t the whole answer.

“On their own, are not enough.”

Our practical guides for the eating side: How to Eat on GLP-1s, Why You Feel Full Faster on Zepbound, and Eating Too Fast on Ozempic?

Action item: Pick one eating habit from those guides and start it this week, whatever drug you’re on or waiting for.

My Picks to Watch

Retatrutide is the one that could reset expectations, if its side effects are manageable. CagriSema is the near-term test of amylin combos. And eloralintide is my dark horse: an amylin drug that, on its own, came close to Zepbound in Phase 2.

What This Means for You

✅ You know the four drugs you can get today

✅ You know CagriSema is next in line

✅ You know why the top of the board isn’t available yet

✅ You read every ranking with trial length, diabetes, and quit rates in mind

✅ You know where to go deeper on each drug

The 5-Minute Version (Screenshot This)

  1. Available now: Zepbound (20.9%), Wegovy (14.9%), Wegovy pill (13.6%), Foundayo (12.4%).
  2. Under review: CagriSema (22.7%), decision expected Q4 2026.
  3. Coming later: retatrutide (28.3%, filing Q1 2027), EloraTZP, eloralintide, MariTide, survodutide.
  4. Fine print: diabetes trials, trial length, and quit rates reorder the board.
  5. Always: the drug changes your appetite; your eating habits still matter.

Conclusion

The 2026 weight-loss drug pipeline is the most crowded it has ever been. The strongest results belong to drugs you can’t get yet. The best choice today is usually one of four approved options, picked for your blockers, not the leaderboard.

Your one action today: write down your blocker, your goal, and your health context, and bring them to your next appointment.

So tell me: which drug on this board are you watching most closely, and why?

Sources